Association Between Hyperuricemia and the Risk of Mortality in Patients with Osteoarthritis: A Study Based on the National Health and Nutrition Examination Survey Database

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2024 May 7

PMID 38713669

Authors

Ye Hao

Xin Tang

Feng Xu

Affiliations

Soon will be listed here.

Abstract

Background: The purpose of this study was to evaluate the relationship between hyperuricemia and the risks of all-cause mortality and cardiovascular disease (CVD) mortality in patients with osteoarthritis (OA).

Methods: A retrospective cohort study was performed on 3,971 patients using data from the National Health and Nutrition Examination Survey database between 1999 and 2018. OA was diagnosed through specific questions and responses. The weighted COX regression models were used to explore the factors associated with all-cause mortality/CVD mortality in OA patients. Subgroup analyses were conducted based on age, gender, hypertension, dyslipidemia, CVD, and chronic kidney disease (CKD). Hazard ratio (HR) and 95% confidence interval (95% CI) were measured as the evaluation indexes.

Results: During the duration of follow-up time (116.38 ± 2.19 months), 33.69% (1,338 patients) experienced all-cause mortality, and 11.36% (451 patients) died from CVD. Hyperuricemia was associated with higher risks of all-cause mortality (HR: 1.22, 95% CI: 1.06-1.41, P = 0.008) and CVD mortality (HR: 1.32, 95% CI: 1.02-1.72, P = 0.036) in OA patients. Subgroup analyses showed that hyperuricemia was related to the risk of all-cause mortality in OA patients aged >65 years (HR: 1.17, 95% CI: 1.01-1.36, P = 0.042), in all male patients (HR: 1.41, 95% CI: 1.10-1.80, P = 0.006), those diagnosed with hypertension (HR: 1.17, 95% CI: 1.01-1.37, P = 0.049), dyslipidemia (HR: 1.18, 95% CI: 1.01-1.39, P = 0.041), CVD (HR: 1.30, 95% CI: 1.09-1.55, P = 0.004), and CKD (HR: 1.31, 95% CI: 1.01-1.70, P = 0.046). The association between hyperuricemia and a higher risk of CVD mortality was found in OA patients aged ≤ 65 years (HR: 1.90, 95% CI: 1.06-3.41, P = 0.032), who did not suffer from diabetes (HR: 1.36, 95% CI: 1.01-1.86, P = 0.048), who did not suffer from hypertension (HR: 2.56, 95% CI: 1.12-5.86, P = 0.026), and who did not suffer from dyslipidemia (HR: 2.39, 95% CI: 1.15-4.97, P = 0.020).

Conclusion: These findings emphasize the importance of monitoring serum uric acid levels in OA patients for potentially reducing mortality associated with the disease.

References

Borghi C, Domienik-Karlowicz J, Tykarski A, Widecka K, Filipiak K, Jaguszewski M . Expert consensus for the diagnosis and treatment of patient with hyperuricemia and high cardiovascular risk: 2021 update. Cardiol J. 2021; 28(1):1-14. PMC: 8105060. DOI: 10.5603/CJ.a2021.0001. View

Cao T, Huynh K, Tran H, Nguyen M . Association between asymptomatic hyperuricemia and knee osteoarthritis in older outpatients. Eur Rev Med Pharmacol Sci. 2022; 26(18):6600-6607. DOI: 10.26355/eurrev_202209_29760. View

Jellinger P, Smith D, Mehta A, Ganda O, Handelsman Y, Rodbard H . American Association of Clinical Endocrinologists' Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis. Endocr Pract. 2012; 18 Suppl 1:1-78. DOI: 10.4158/ep.18.s1.1. View

Han Y, Cao Y, Han X, Di H, Yin Y, Wu J . Hyperuricemia and gout increased the risk of long-term mortality in patients with heart failure: insights from the National Health and Nutrition Examination Survey. J Transl Med. 2023; 21(1):463. PMC: 10339518. DOI: 10.1186/s12967-023-04307-z. View

Cho S, Chang Y, Kim I, Ryu S . U-Shaped Association Between Serum Uric Acid Level and Risk of Mortality: A Cohort Study. Arthritis Rheumatol. 2018; 70(7):1122-1132. DOI: 10.1002/art.40472. View

Li L, Zhao M, Wang C, Zhang S, Yun C, Chen S . Early onset of hyperuricemia is associated with increased cardiovascular disease and mortality risk. Clin Res Cardiol. 2021; 110(7):1096-1105. DOI: 10.1007/s00392-021-01849-4. View

Wang Y, Li J, Sun X, Lai R, Sheng W . High serum uric acid levels are a protective factor against unfavourable neurological functional outcome in patients with ischaemic stroke. J Int Med Res. 2018; 46(5):1826-1838. PMC: 5991245. DOI: 10.1177/0300060517752996. View

Musacchio E, Perissinotto E, Sartori L, Veronese N, Punzi L, Zambon S . Hyperuricemia, Cardiovascular Profile, and Comorbidity in Older Men and Women: The Pro.V.A. Study. Rejuvenation Res. 2016; 20(1):42-49. DOI: 10.1089/rej.2016.1834. View

Scanzello C . Role of low-grade inflammation in osteoarthritis. Curr Opin Rheumatol. 2016; 29(1):79-85. PMC: 5565735. DOI: 10.1097/BOR.0000000000000353. View

10.

Leung Y, Haaland B, Huebner J, Wong S, Tjai M, Wang C . Colchicine lack of effectiveness in symptom and inflammation modification in knee osteoarthritis (COLKOA): a randomized controlled trial. Osteoarthritis Cartilage. 2018; 26(5):631-640. DOI: 10.1016/j.joca.2018.01.026. View

11.

Hawker G, King L . The Burden of Osteoarthritis in Older Adults. Clin Geriatr Med. 2022; 38(2):181-192. DOI: 10.1016/j.cger.2021.11.005. View

12.

Hunter D, Bierma-Zeinstra S . Osteoarthritis. Lancet. 2019; 393(10182):1745-1759. DOI: 10.1016/S0140-6736(19)30417-9. View

13.

Joosten L, Crisan T, Bjornstad P, Johnson R . Asymptomatic hyperuricaemia: a silent activator of the innate immune system. Nat Rev Rheumatol. 2019; 16(2):75-86. PMC: 7075706. DOI: 10.1038/s41584-019-0334-3. View

14.

Zhao J, Sha B, Zeng L, Dou Y, Huang H, Liang G . J-shaped association of serum uric acid concentrations with all-cause mortality in individuals with osteoarthritis: A prospective cohort study. Joint Bone Spine. 2023; 91(3):105679. DOI: 10.1016/j.jbspin.2023.105679. View

15.

Zhu Y, Li J, Zhang Y, Zhang W, Doherty M, Yang Z . Association between hyperuricaemia and hand osteoarthritis: data from the Xiangya Osteoarthritis Study. RMD Open. 2023; 9(4). PMC: 10693871. DOI: 10.1136/rmdopen-2023-003683. View

16.

de Campos G, Mundi R, Whittington C, Toutounji M, Ngai W, Sheehan B . Osteoarthritis, mobility-related comorbidities and mortality: an overview of meta-analyses. Ther Adv Musculoskelet Dis. 2021; 12:1759720X20981219. PMC: 7768583. DOI: 10.1177/1759720X20981219. View

17.

Srivastava A, Kaze A, McMullan C, Isakova T, Waikar S . Uric Acid and the Risks of Kidney Failure and Death in Individuals With CKD. Am J Kidney Dis. 2017; 71(3):362-370. PMC: 5828916. DOI: 10.1053/j.ajkd.2017.08.017. View

18.

McClure S, Schlechter H, Oh S, White K, Wu B, Pilla S . Dietary intake of adults with and without diabetes: results from NHANES 2013-2016. BMJ Open Diabetes Res Care. 2020; 8(1). PMC: 7590352. DOI: 10.1136/bmjdrc-2020-001681. View

19.

. Global, regional, and national burden of osteoarthritis, 1990-2020 and projections to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Rheumatol. 2023; 5(9):e508-e522. PMC: 10477960. DOI: 10.1016/S2665-9913(23)00163-7. View

20.

Nishizawa H, Maeda N, Shimomura I . Impact of hyperuricemia on chronic kidney disease and atherosclerotic cardiovascular disease. Hypertens Res. 2022; 45(4):635-640. DOI: 10.1038/s41440-021-00840-w. View